Crescent Biopharma (CBIO) Reiterated at Buy by Stifel on CR-003/SKB105 Potential
Tweet Send to a Friend
Stifel analyst Stephen Willey reiterated a Buy rating and $30.00 price target on Crescent Biopharma Inc (NASDAQ: CBIO).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
